BMS-986020治疗特发性肺纤维化的随机双盲安慰剂对照2期试验
该2期试验纳入143例IPF患者,随机接受安慰剂或BMS-986020 600mg每日一次或每日两次治疗26周。每日两次组FVC下降速率较安慰剂显著减慢,但两种方案均出现肝酶升高,且因3例胆囊炎研究提前终止。
要点
- BMS-986020 600mg每日两次可显著减缓IPF患者FVC下降速率。
- 两种BMS-986020方案均与剂量相关的肝酶升高相关。
- 因3例与药物相关的胆囊炎,研究提前终止。
核心结论
- BMS-986020 600mg每日两次治疗26周较安慰剂显著减缓FVC下降速率。
- 两种BMS-986020方案均与肝酶升高相关,且因胆囊炎研究提前终止。
研究设计与样本
- IM136003为2期、平行组、多中心、随机、双盲、安慰剂对照试验。
- 纳入成人IPF患者,FVC 45%-90%,DLCO 30%-80%,随机接受安慰剂或BMS-986020 600mg每日一次或每日两次治疗26周。
主要发现
- 两种BMS-986020治疗组均观察到剂量相关的肝酶升高。
- 揭盲后确定3例胆囊炎与BMS-986020相关,研究提前终止。
关键数值与推荐
- 主要终点为基线至第26周FVC变化率。
临床怎么用
- BMS-986020每日两次方案显示延缓FVC下降的潜力,但需监测肝酶和胆囊相关不良事件。
- 因安全性问题研究提前终止,该药尚未进入临床常规使用。
局限性
- 研究因3例胆囊炎提前终止,可能影响完整安全性评估。
- 样本量有限(143例随机),完成26周给药者108例。
- 原文未报告其他局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Idiopathic pulmonary fibrosis (IPF) causes irreversible loss of lung function. The lysophosphatidic acid receptor 1 (LPA1) pathway is implicated in IPF etiology. Safety and efficacy of BMS-986020, a high-affinity LPA1 antagonist, was assessed vs placebo in a phase 2 study in patients with IPF. METHODS: IM136003 was a phase 2, parallel-arm, multicenter, randomized, double-blind, placebo-controlled trial. Adults with IPF (FVC, 45%-90%; diffusing capacity for carbon monoxide, 30%-80%) were randomized to receive placebo or 600 mg BMS-986020 (once daily [qd] or bid) for 26 weeks. The primary end point was rate of change in FVC from baseline to week 26. RESULTS: Of 143 randomized patients, 108 completed the 26-week dosing phase. Thirty-five patients discontinued prematurely. Patient baseline characteristics were similar between treatment groups (placebo: n = 47; 600 mg qd: n = 48; 600 mg bid: n = 48). Patients treated with BMS-986020 bid experienced a significantly slower rate of decline in FVC vs placebo (-0.042 L; 95% CI, -0.106 to -0.022 vs -0.134 L; 95% CI, -0.201 to -0.068, respectively; P = .049). Dose-related elevations in hepatic enzymes were observed in both BMS-986020 treatment groups. The study was terminated early because of three cases of cholecystitis that were determined to be related to BMS-986020 after unblinding. CONCLUSIONS: BMS-986020 600 mg bid treatment for 26 weeks vs placebo significantly slowed the rate of FVC decline. Both regimens of BMS-986020 were associated with elevations in hepatic enzymes. TRIAL REGISTRY: ClinicalTrials.gov; No.: NCT01766817; URL: www.clinicaltrials.gov.
引用
- Palmer SM, Snyder L, Todd JL, et al. Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial of BMS-986020, a Lysophosphatidic Acid Receptor Antagonist for the Treatment of Idiopathic Pulmonary Fibrosis. Chest. 2018. PMID: 30201408. doi:10.1016/j.chest.2018.08.1058
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。